Table 1.

Basic characteristics according to chemotherapeutic conditioning regimen

Baseline characteristic	Total (N = 191)		Chemotherapeutic conditioning regimen				P
			Flu/Thio/Bu (n = 100)		Flu/Thio/Treo (n = 91)
Sex, n (%)							.564
Male	107	56%	58	58%	49	54%
Female	84	44%	42	42%	42	46%
Age at HSCT, y, n (%)
<2 y	90	47%	42	42%	48	53%	.137
≥2	101	53%	58	58%	43	47%
Age at diagnosis, n (%)
<6 mo	58	30%	27	27%	31	34%	.325
6 mo-1 y	34	18%	16	16%	18	19%
≥1 y	99	52%	57	57%	42	46%
Immunophenotype
BCP	156	82%	86	86%	70	77%	.140
T-cell ALL	28	15%	13	13%	15	16%
Other	6	3%	1	1%	5	5%
Unknown	1	1%		0%	1	1%
Donor, n (%)
MSD	37	19%	23	23%	14	15%	.184
MUD	154	81%	77	77%	77	85%
Remission status, n (%)
CR1	139	73%	67	67%	72	79%	.098
CR2	50	26%	31	31%	19	21%
CR3	2	1%	2	2%	0	0%
Stem cell source, n (%)
Bone marrow	131	69%	63	64%	68	75%	.041
Peripheral blood	35	18%	17	17%	18	20%
Cord blood	23	12%	18	18%	5	5%
Bone marrow + peripheral blood	1	1%	1	1%	0	0%
Unknown∗	1	1%	1	1%	0	0%
MRD before HSCT, n (%)
Low load (<10−4)	105	70%	62	77%	43	61%	.044
High load (≥10−4)	46	30%	19	23%	27	39%
Genetic aberration, n (%)
KMT2A-AFF1	51	29%	24	26%	27	32%	.465
ETV6-RUNX1	6	3%	4	4%	2	2%
BCR-ABL†	13	7%	9	10%	4	5%
None of the above	108	61%	56	60%	52	61%
Unknown∗	13	7%	7	7%	6	7%
Hypodiploidy, n (%)
No	169	99%	88	99%	81	99%	.954
Yes	2	1%	1	1%	1	1%
Unknown∗	20	10%	11	11%	9	10%
Hyperdiploidy, n (%)
No	149	87%	76	85%	73	88%	.622
Yes	23	13%	13	15%	10	12%
Unknown∗	19	10%	11	11%	8	9%
Time of relapse, mo, n (%)
<18	32	67%	18	60%	14	78%	.390
18-30	15	31%	11	37%	4	22%
>30	1	2%	1	3%	0	0%
Unknown∗	2	4%	1	3%	1	5%
Type of relapse, n (%)
Bone marrow	29	58%	19	61%	10	53%	.807
CNS	10	20%	6	19%	4	21%
Other	11	22%	6	19%	5	26%

Percentages were calculated using evaluable patients as the denominator, unless otherwise stated.

BCP, B-cell precursor; CNS, central nervous system.

^∗Percentage based on the total number of patients.

^†Includes 1 patient with BCR-ABL and KMT2a-AFF1 and 2 patients with BCR-ABL and ETV6-RUNX1.